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Background: Ochratoxin A (OTA) is a mycotoxin produced by fungal species of Aspergillus 
and Penicillium. OTA is nephrotoxic and carcinogenic in several animal models; it frequently 
contaminates human and animal food products. Chronic exposure is associated with 
progressive renal fibrosis in humans (Balkan endemic nephropathy). Resveratrol is a 
phytoalexin that possesses both anti-cancer and antioxidant properties. We investigated the 
mechanism of cellular oxidative stress induced by OTA in the human embryonic kidney 
(HEK293) cell line. 
Methods: An IC50 value of 1.5µM was determined from a dose-dependent cell viability curve 
using the methylthiazol tetrazolium (MTT) assay on HEK293 cells treated with a range of OTA 
concentrations (0.25µM–50µM) for 24hrs. Glutathione levels were quantified by luminometry 
and gene expression of Nrf2, OGG1, CAT, SOD and GPx was determined by qPCR. Protein 
expression of Nrf2 and phosphorylated SIRT1 (pSIRT1) was assessed by western blot, DNA 
damage was determined using the comet assay, and flow cytometry was employed for 
intracellular ROS detection. 
Results: Resveratrol decreased mRNA expression of OGG1 (p<0.05) and OTA significantly 
increased OGG1 expression (p<0.05). The comet assay proved that while OTA induced DNA 
damage, resveratrol protected the DNA against strand breaks. Both resveratrol and OTA 
significantly increased antioxidant defence gene expression (Nrf2, CAT, GPx and SOD) 
(p<0.05). OTA decreased intracellular ROS, while resveratrol-treated cells exhibited the lowest 
percentage of intracellular ROS. Luminometry analysis showed the OTA+Resveratrol co-
treatment to have a synergistic effect on the concentration of GSH and GSSG. Western blot 
analysis of protein showed that resveratrol significantly increased the levels of pSIRT1 while 
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concomitantly decreasing the protein levels of Nrf2 (p<0.05) and OTA significantly decreased 
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Ochratoxin A (OTA) is a common contaminant of foods, such as grains, fruit and animal feed 
[5]. It is ubiquitously produced by fungal species of Aspergillus and Penicillium, specifically 
Aspergillus ochraceus [6]. Rural populations in developing countries rely heavily on grains as 
a staple source of sustenance; many of these communities lack proper storage facilities for 
harvested grains; this leads to increased fungal contamination and subsequent production of 
OTA [7]. Ochratoxin A was first discovered in South Africa (SA) in 1965 [8] and has since 
been found in food sources around the world [9]. Although first discovered in SA, there is still 
little documented information on OTA mycotoxicosis in SA. Understanding the mechanism of 
OTA toxicity is particularly important for African countries since grains, such as cassava and 
maize, contribute to a large part of the daily sustenance for a high percentage of the population 
[9].  
 
Microorganisms in the gastrointestinal tract (GIT) hydrolyse OTA to the less toxic by-product, 
Ochratoxin α (OTα) [10], which is then excreted via the liver and kidney [11]. Exposure to 
high levels of OTA has also been linked to renal dysfunction and tumourigenesis in humans 
[12]. OTA is nephrotoxic and results in destruction of the renal tubular epithelium causing 
progressive renal failure [1]. This disease is particularly prominent in the Balkan regions such 
as Bulgaria and Romania, and is known as Balkan Endemic Nephropathy (BEN) [1].  
 
OTA exerts its toxic effects via a number of mechanisms, the most prominent method is by 
induction of oxidative stress, thereby increasing the production of reactive oxygen species 
(ROS) [13]. OTA alters the antioxidant potential of the cell, increasing the oxidative stress 
placed on the cell [14]. During oxidative stress nuclear factor-erythroid 2-related factor 2 
xxii 
  
(Nrf2) dissociates from its inhibitor, Kelch-like ECH-associated protein 1 (Keap-1), 
translocates into the nucleus and binds to the antioxidant response element (ARE) resulting in 
the transcription of proteins associated with the antioxidant defence system [15].  
 
Resveratrol (3, 4’, 5-trihydroxy-trans-stilbene) is a polyphenol found in the skin of injured 
grapes and some fruit, and is therefore commonly present in wine and grape juice [16]. 
Resveratrol is synthesised by plants as a defensive mechanism and is proposed to have 
antimicrobial, antioxidant, anti-carcinogenic and anti-inflammatory properties [16]. This 
compound is widely studied and holds great potential in disease treatment. It is also thought to 
promote cardiovascular health and longevity of cells, and is therefore encouraged as part of a 
healthy diet [17]. Resveratrol possesses free radical scavenging potential, contributing to its 
antioxidant capacity [18]. The phytoalexin is also known to activate Sirtuin 1 (SIRT1), an 
NAD+-dependent deacetylase known for its ability to modulate transcription of proteins that 
augment the oxidative stress response as well as proteins that promote cell survival in times of 
stress [18, 19]. These attributes could contribute to the compound’s chemo-preventive ability, 
as well as the ability to diminish cellular damage due to oxidative stress [17].  
 
The mechanisms of OTA toxicity and the cellular antioxidant response are relatively unknown. 
We investigated the cytotoxic effects of OTA on HEK293 cells after acute exposure (24hr). 
Thereafter, we investigated the therapeutic effects of resveratrol in untreated and OTA-treated 
HEK293 cells. The results can be used as insight into the effects of OTA in human kidney cells, and 






Aims and Objectives 
 
Aim: 
To determine the therapeutic effects of resveratrol in human embryonic kidney (HEK293) cells 
exposed to Ochratoxin A.  
 
Objectives: 
- Investigate the antioxidant response in HEK293 cells when exposed to OTA and 
resveratrol.  The antioxidant response of the kidney cells will be observed by measuring 
certain markers associated with the antioxidant response, such as Nrf2, catalase, 
superoxide dismutase, glutathione peroxidase and glutathione. The mRNA and protein 
expression of these markers will be measured.  
- Determine the effects of both OTA and resveratrol on the DNA of HEK293 cells.  The 
genotoxic potential of OTA will be observed by measuring strand breaks in DNA. 
Thereafter, the therapeutic effects of resveratrol will be investigated by measuring 
biomarkers associated with DNA damage repair, such as OGG1.  
- Investigate the extent of ROS induction in HEK293 cells. The oxidative stress 






1. Literature Review 
 
1.1 Ochratoxin A: The Mysterious Mycotoxin 
Ochratoxin A (OTA) is a ubiquitous mycotoxin, produced by species of Penicillium and 
Aspergillus fungi, specifically P. verrucosum and A. ochraceus. This mycotoxin frequently 
contaminates food products, such as cereals, grains, coffee, some fruits and even pork products 
if contamination of animal feed occurs. This contamination occurs when foods are incorrectly 
stored and fungal growth infects the food [20-24]. OTA is a chlorinated isocoumarin 
compound, which consists of a dihydroisocoumarin moiety linked to L-phenylalanine by a 
carboxyl group (Figure 1). Much controversy surrounds this mycotoxin, as an exact mechanism 
to its toxicity or metabolic pathway has not yet been elucidated. Much data has been collected 
on OTA since its discovery in South Africa in 1965, however a clear mechanism of action has 
not yet been found [8]. There are many proposed mechanisms of toxicity, and these could all 
contribute to the overall toxicity of OTA, which is known to be nephrotoxic and carcinogenic 











1.1.1 Toxicity of OTA 
OTA exerts its toxic effects via a number of pathways, such as oxidative stress induction, 
protein synthesis inhibition, signal transduction disruptions and metabolic disturbances. These 
mechanisms can eventually lead to renal failure and carcinogenesis [25]. This end point is 
common in populations from the Balkan Peninsula (Figure 2), thus it has been termed Balkan 
Endemic Nephropathy (BEN). This disease is characterised by progressive renal failure, often 
occurring in individuals aged 30 to 40 years, occasionally accompanied by urinary tract 
tumours (UTT) [26]. Many studies have been conducted in this region of Europe involving 
consumer testing, which revealed OTA contamination in frequently consumed foods [13]. 
Thus, OTA has been linked as a causal factor in BEN. Subsequent testing using rodents has 
















1.1.1.1 Oxidative stress induction by OTA 
Reactive oxygen species (ROS) formation occurs endogenously and is pivotal in normal 
cellular functions as well as during protective processes, such as the release of ROS from 
phagocytic cells to facilitate the destruction of infected or damaged cells. However, when ROS 
production outweighs the antioxidant capacity of the cell, cytotoxic situations arise [29].  
 
The formation of ROS by OTA has been well documented, and this is often presented as the 
most feasible mechanism of toxicity. OTA is thought to disrupt the antioxidant defence 
response by inducing ROS formation at a rate too great for the cell to cope with [30]. OTA 
involvement in Fenton reactions has been documented; it is thought that the chlorine atom is 
involved in iron chelation, thus promoting the progression of Fenton reactions (Figure 3), 
fundamentally increasing the overall generation of ROS, with emphasis on hydroxyl radicals 




Figure 3: Production of hydroxyl radicals by the Fenton reaction [2].  
 
It has also been frequently reported that OTA down-regulates proteins associated with 
antioxidant defence systems, thus rendering the cell vulnerable to ROS-mediated attack. ROS 
can modify the behaviour of a cell and hence influence its survival (Figure 4) [1, 6, 32]. 
 
Mitochondrial functioning is affected by OTA, this could promote the release of electrons from 
the electron transport chain (ETC), contributing to the formation of superoxides [33]. 
Superoxides (O2
-) are a form of free radicals, as are hydrogen peroxides (H2O2) and OH
-. The 
Fe (II) + H2O2  OH
- + OH +Fe (III)  
4 
  
hydroxyl radical is very reactive with biological molecules, such as lipids, proteins and DNA 















Figure 4: ROS affects DNA, lipids and proteins, contributing to dysfunctional cellular 
processes and aging. 
 
1.1.1.2 Genotoxicity of OTA 
Some authors state that OTA is directly genotoxic, and others believe that the toxin indirectly 
induces DNA damage by increasing ROS production. OTA can induce DNA strand breaks by 
increasing the formation of ROS, while simultaneously diminishing the antioxidant defence of 
the cell, which would allow free radicals to interact with DNA [34]. DNA strand breakage 
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when it abstracts hydrogen (H+) atoms from methyl groups of the base thymine [33]. The 
addition of OH- into double bonds yields adduct radicals, while H+ abstraction yields allyl 
radicals. These radicals then undergo a number of reactions, ultimately resulting in multiple 
DNA products; if the antioxidant response is not functioning optimally then this array of DNA 
bases would persist and eventually alter the structure and functioning of the genome, resulting 
in mutations [33]. DNA damage is a crucial event in the initiation of carcinogenesis. Many 
studies report that OTA always induces DNA fragmentation, however, it is unknown whether 
the toxin achieves this directly or indirectly. It is thought that OTA-mediated ROS induction 
and oxidative damage could contribute to the toxicity and carcinogenicity of OTA [34].  
 
1.1.1.3 Calcium homeostasis disruptions  
The second early event of ROS-induced damage is altered Ca2+ homeostasis. Calcium is an 
important second messenger and is responsible for the transfer of biological information. It is 
paramount in maintaining the proper functioning of cells, however, if not strictly regulated, 
fluctuations in Ca2+ homeostasis could be detrimental and possibly fatal to the cell [35]. OTA 
plays a role in the disruption of Ca2+ homeostasis, possibly contributing to its toxicity (Figure 
5). The cell experiences increased calcium influx as well as increased release of calcium from 
stores, such as the endoplasmic reticulum (ER). Calcium sensitive channels are affected during 
this disrupted homeostasis, therefore OTA has the potential to disrupt all cellular functions that 
are calcium-dependent [32]. OTA promotes lipid peroxidation via increased ROS production; 
lipid peroxidation compromises the plasma membrane structure, thereby altering its 
permeability to Ca2+ ions, this in turn compromises Ca2+ homeostasis [32]. The OH- radical 
exerts its effect on lipids by abstracting H+ from polyunsaturated fatty acids (PUFAs) and 
thereby setting off a chain reaction, resulting in the mass formation of free radicals. This 




Figure 5: The effects of increased intracellular calcium as a mechanism of OTA toxicity. 
 
1.1.1.4 Protein synthesis disruptions  
The structure of OTA plays a crucial role in its mechanisms of toxicity. This mycotoxin 
possesses a phenylalanine (Phe) moiety, therefore allowing it to behave as a structural analogue 
to Phe [32]. OTA is able to mimic the amino acid and act on the systems that Phe is naturally 
involved in; it is by this method that OTA affects protein synthesis, Phe metabolism and, 
subsequently, enzyme production (Figure 6). Protein synthesis is affected by competitive 
inhibition of the enzyme phenylalanine-tyrosine (Phe-Tyr) synthase, the toxin inhibits Phe 
participation in this reaction by competing for the enzyme, in this manner peptide elongation 
as well as amino acylation is halted [36, 37]. Phe metabolism is disrupted by the interaction of 
OTA with Phe-hydroxylase; this enzyme is responsible for the conversion of Phe to Tyr during 
an irreversible hydroxylation reaction, which is an important step of Phe catabolism [37]. 
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A mechanism of OTA toxicity could be the inhibition of Phe-hydroxylase or participation as a 
substrate for the enzyme, in place of Phe, by binding to specific activation sites on the enzyme 
and impairing the normal reaction. In this way OTA competes against Phe for its enzyme. The 
catabolism of Phe is tightly regulated to prevent the depletion or accumulation of Phe to 
unnatural levels, which could lead to decreased production of Phe requiring compounds. The 
involvement of OTA in this metabolic pathway could lead to phenylketonuria [32]. As a 
consequence to protein synthesis inhibition, enzyme synthesis is impaired, particularly 
affecting phosphoenolpyruvate carboxykinase (PEPCK). This is a fundamental enzyme in the 












Figure 6: Toxicity of the OTA phenylalanine moiety. 
 
1.1.2 Exposure, Absorption and Distribution 
OTA exposure occurs via ingestion of contaminated food, such as grains, fruit, coffee beans, 
wines and animal products. Aspergillus and Penicillium fungi are responsible for the 
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production of OTA as a secondary metabolite during fungal contamination of foods. The 
toxicokinetics of OTA are difficult to follow since the toxin is involved in many reactions in 
vivo. Once OTA is ingested it is present in the mono-anion and di-anion forms in the duodenum 
due to the pH of chyme, it can then be passively absorbed in its non-ionised and mono-anion 
form. It can be readily absorbed from the small intestine into the blood where it becomes 99% 
bound to serum proteins, especially albumin [34]. The serum half-life in humans is the longest 
recorded half-life of OTA (35 days), however variations in the half-life exists depending on 
the degree of binding or the protein binding affinity.  When OTA is protein-bound it becomes 
more difficult to eliminate, passive absorption is facilitated and as a result the half-life can 
become extended in vivo [1]. Albumin binding prevents toxin transfer from the blood to renal 
or hepatic cells, thus preventing its biotransformation for excretion purposes.  
 
The concentration of OTA and its metabolites in vivo depend on a number of factors, namely 
animal species, the dose and forms of administered OTA, the diet composition and health status 
of the animal. Once OTA has been absorbed into the blood stream, it is transported to the 
kidney and other tissues [1]. In the kidney, specific organic anion transporters (OAT) facilitate 
cellular uptake. Since the toxin is protein-bound it can be absorbed at the proximal and distal 
tubules of the kidney, resulting in toxin accumulation in the kidney [32]. OTA has also been 
detected in human milk, which poses a considerable health risk to breast-feeding infants [9]. 
Kumagai et al. (1982) and Roth et al (1988) provided evidence that OTA participates in 
enterohepatic recycling. These studies have shown that a secondary OTA distribution peak was 
observed in the serum and intestine of rodents, which could be due to the process of 





1.1.3 Biotransformation & Elimination  
Areas of high biotransformation, such as the liver and kidney, possess the potential to transform 
OTA into less toxic compounds using Phase I biotransformation reactions [40]. OTA is 
excreted via biliary (faeces) and renal (urine) routes, thus it interacts closely with the liver and 
kidney, which places these organs in a high risk situation, as OTA could easily exert toxic 
effects on hepatic and renal cells. Since OTA has a high affinity for plasma proteins, it is 
difficult to excrete the parent compound via glomerular filtration [1]. The toxin can also be 
reabsorbed at all nephron segments inducing an accumulation effect in the kidney and 
decreasing elimination. The highest concentrations of OTA can be found in the renal papilla 
and the medulla as a direct consequence of tubular reabsorption [32]. Biotransformation of the 
parent compound occurs to combat the persistence of OTA. OTA undergoes a number of 
reactions, yielding a variety of metabolic derivatives, each with its own set of characteristics 
and levels of toxicity (Figure 7).  
 
Hydrolysis of the parent molecule occurs in the large intestine in the presence of 
microorganism-rich digesta [41]. OTA is converted to Ochratoxin α (OTα) when the peptide 
bond is cleaved by proteases, liberating the Phe moiety from the chlorinated 
dihydroisocoumarin moiety. It is thought that the microorganisms in the gut are responsible for 
this reaction; this information was used to conclude that ruminants enjoy an increased 
resistance to the toxic effects of OTA since the rumen of these animals contains higher levels 
of microorganisms, elevating the degradation of OTA to compounds that can be easily 
eliminated [10]. It has been proposed by Hohler et al (1999) that ruminants could be used to 
remove OTA from the food chain by feeding contaminated food to the animals, and allowing 
them to degrade the toxin [10]. Phase I reactions produce hydroxylated derivatives of OTA, 
namely 4(R)-OH OTA, 4(S)-OH OTA, 10-OH OTA, this can be achieved by the incubation of 
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OTA with liver and kidney microsomes. A small amount of the parent compound is converted 
to these hydroxylated derivatives by cytochrome P450 isoforms (CYP450 
1A1/1A2/2B1/3A1/3A2). The hydroxylated derivatives are less toxic than the parent compound 














Figure 7: Biotransformation of OTA into various metabolites for detoxification (Adapted by 
author from Ringot et al., (2006)). 
 
Ochratoxin B (OTB) is a dechloro-derivative of OTA and is far less toxic, possibly due to the 
lack of a chlorine atom, which decreases the ability of the toxin to chelate iron and thus 
decreases participation in Fenton reactions [32]. In the case of OTα, the phenylalanine moiety 
is removed, therefore decreasing the inhibition of protein synthesis and metabolic disturbances 












biotransformation is not always beneficial. The parent molecule could form a lactone-opened 
OTA (OP-OTA), as seen by Xiao et al (1996). The formation of this derivative is not clearly 
understood, however, it has been found to undergo clearance at a far slower rate that OTA and 
it appears to be extremely toxic in rats [42]. 
 
The kidney has been identified as the target organ of OTA, thus it experiences the brunt of 
OTA toxicity. The kidney attempts to eliminate OTA by excreting the parent compound or its 
derivatives in urine. However, during this process some reabsorption occurs, glomerular 
filtration is limited and OTA accumulates in the kidney, thus increasing the toxin’s contact 
time with renal cells. Heussner et al. (2007) suggested that repeated exposure of renal 
epithelium to OTA altered the normal structure and functioning of the tissue. This research 
indicated that renal epithelium experienced a conversion to a more fibroblast-like nature, as 
fibroblasts are less vulnerable to the effects of OTA [43]. During this conversion the cell 
increases collagen production. OTA exposure induces renal cell death, and the kidney attempts 
to compensate for this cell death by augmenting the repair and regenerative processes. This 
process involves the migration and proliferation of renal cells, during proliferation the cells 
undergo differentiation, which alters the cell type and steers it towards fibroblast characteristics 
[43]. These changes in renal cells result in progressive fibrosis, which is a late stage event seen 
in BEN. OTA-induced nephrotoxicity can be recognised by glucosuria, proteinuria and renal 
dysfunction, which can be confirmed by observing increased urea and creatinine levels in the 
blood as well as decreased glucose and protein in the serum. 
 
1.2 Resveratrol: Therapeutic Potential 
Resveratrol is a phytoalexin frequently produced by plants in response to cellular damage or 
fungal infection. This compound is commonly found in the skins of grapes, Vitis vinifera, as a 
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response to ultraviolet (UV) damage or infection with Botrytis cinerea [16]. The phytoalexin 
is known to have a vast array of health benefits and dates back to its use in Chinese and Japanese 
traditional medicine [19]. The compound was first isolated in 1940 by Michio Takaoka from 
the roots of white hellebore, a flowering plant belonging to the family Ranunculaceae [44, 45]. 







Figure 8: Image of Botrytis cinerea infection on grapes commonly used for wine production. 
 
1.2.1 Description & Distribution 
Trans-resveratrol was first discovered in the skins of grapes in 1976 by Langcake and Pryce 
[46]. It has since been studied and synthesised organically; the compound can remain stable 
for many months if protected from light [47]. Resveratrol is commonly found in wines and 
grape juice as a result of the compounds presence in grape skins, it can also be found in berries, 
peanuts and other plant sources. One gram of grape skin can contain anywhere from 50µg to 
100µg resveratrol [16]. 
 
The concentration of resveratrol present in wines depends on a number of factors; namely, the 
type of grape, the geographic region of grape growth, the severity of Botrytis infection, the type 
of wine being produced (since maceration time influences the degree of grape skin injury) and 
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Figure 9: Structure of resveratrol [3]. 
 
1.2.2 Bioavailability and Metabolism  
Resveratrol is frequently ingested with food products, it is easily absorbed from the GIT and 
rapidly metabolised in the liver by phase II biotransformation enzymes which render the 
compound soluble in water. Glycosylated resveratrol is said to be more stable and serves to 
protect the compound from oxidative degradation [16]. Resveratrol can possibly accumulate in 
epithelial cells along the aerodigestive tract; and these metabolites could contribute to the 
cardiovascular protective and chemopreventive properties of resveratrol.  
 
Three main pathways are functional in the metabolism of resveratrol. This phytoalexin can 
undergo sulphate and glucuronic acid conjugation of phenolic groups, as well as hydrogenation 
of the aliphatic double bond, which is thought to be carried out by microflora residing in the 
intestine [48]. Sulphate and glucuronic acid conjugates have been found in the urine. Trace 
amounts of unchanged resveratrol have been discovered in systemic circulation, while trans-




[16]. The bioavailability and efficacy of resveratrol metabolites is unknown and further 
research needs to be conducted on this subject.   
 
1.2.3 Antioxidant effects 
Resveratrol has been proven to possess a multitude of antioxidant effects ranging from the 
ability to decrease lipid peroxidation, scavenge free radicals and chelate copper [47, 49-51]. 
Bradamante et al. (2004) reported that resveratrol scavenges hydroxyl and superoxide radicals. 
It also has the ability to scavenge metal-induced radicals, thus preventing lipid peroxidation 
and low-density lipoprotein (LDL) oxidation by diminishing the involvement of Fe2+ and Cu2+ 
in the respective reactions [52]. Resveratrol is known to exert protective effects over the kidney 
by modulating the expression of protective enzymes, such as glutathione peroxidase (GPx), 
superoxide dismutase (SOD) and catalase (CAT) through nuclear factor-erythroid 2-related 
factor 2 (Nrf2) -mediated regulation, resulting in decreased renal oxidative stress [53].  
 
1.2.4 Anti-inflammatory properties  
Resveratrol has been linked to anti-inflammatory abilities, similar to that of non-steroidal anti-
inflammatory drugs (NSAIDs), whereby it inhibits cyclooxygenase (COX) activity, thus 
preventing COX-mediated arachidonic acid conversion to prostaglandins [54]. Decreased 
prostaglandin synthesis would contribute to decreased platelet aggregation and increased 
vasodilation that accompanies resveratrol exposure [55].  
 
1.2.5 Chemopreventive potential 
Taken together, the antioxidant and anti-inflammatory properties of resveratrol can contribute 
to chemoprevention [56-58]. As indicated by Jang et al. (1996), resveratrol is able to prevent 
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the three major stages of carcinogenesis, namely, initiation, promotion and progression. Firstly, 
the authors provided evidence that resveratrol prevents initiation by behaving as an antioxidant 
and antimutagen. The compound performs this feat by inducing phase II drug-metabolising 
enzymes, such as quinone reductase, which serves to detoxify carcinogens. Secondly, the anti-
inflammatory effects result in the inhibition of COX-1, which prevents an inflammatory 
environment by decreasing the production of prostaglandins [17]. Prostaglandins are known to 
stimulate tumour growth as well as diminish immune system efficiency, while COX-1 
participates in the activation of carcinogens to reactive intermediates that could induce DNA 
damage.  
 
Resveratrol can also inhibit protein kinase C (PKC), which is responsible for COX activation. 
Therefore, resveratrol also serves to protect DNA from carcinogen attack. Thirdly, resveratrol 
has been recorded inducing differentiation, which would prevent tumour progression, in human 
promyelocytic leukaemia cells [54].  
 
1.2.6 Cardiovascular protection  
Resveratrol exerts protective effects on the cardiovascular system. Many authors refer to the 
“French Paradox” as a testament to the cardiovascular protective effects of resveratrol [50, 51]. 
This phenomenon illustrates that although the French people enjoy a diet high in saturated fats, 
the frequent consumption of red wine decreases death by coronary heart disease (CHD) [59]. 
An interest in red wine was piqued and resveratrol was discovered as the specific compound 

















Figure 10: Chemopreventive effects of Resveratrol. 
 
The antioxidant and anti-inflammatory characteristics of resveratrol also contribute to its 
cardiovascular protective properties. Reduction of free radicals, as a result of resveratrol-
mediated free-radical scavenging, in turn decreases the extent of LDL oxidation, which 
ultimately contributes to CHD, since oxidised LDL can be found in atherosclerotic lesions [61, 
62]. Resveratrol also serves to decrease serum lipid levels through an undefined mechanism. 
Platelet aggregation is diminished by resveratrol due to its apoptosis and thrombosis disrupting 
attributes [47, 63-66]. Resveratrol has the ability to inhibit thromboxane B2, a stable metabolite 
of thromboxane A2, thereby decreasing vasoconstriction. The COX pathways also mediate the 
state of vascular endothelium, governing vasoconstriction or vasodilation. In this manner, 
resveratrol serves to protect the cardiovascular system [52].  
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1.2.7 Resveratrol, Sirtuin 1 and Aging 
The hallmarks of aging include decreased cellular responsiveness to stress, disruptions in 
cellular homeostasis and eventual organ dysfunction. Calorie restriction (CR) has been found 
to decrease the effects of aging, delay the onset of age-related diseases and extend lifespan 
[67]. The silent information regulator 2 (Sir2), found in Saccharomyces cerevisiae (yeast), has 
been identified as a molecule that participates in the process by which CR mediates cellular 
health and extends life [17, 68]. Sirtuin 1 (SIRT1) is an NAD+-dependent deacetylase, which 
is a mammalian homologue to Sir2 and has been proven to function in a similar manner [69].  
SIRT1 functions in metabolic and cellular stress response by altering certain cellular processes 
upon receiving stress signals. The main function of SIRT1 is to promote cell survival and 
confer resistance to stress-induced cytotoxicity. This deacetylase modulates cellular response 
to stress, in order to decrease oxidative damage and prevent replication of damaged DNA, 
thereby reducing the chance of mutation accumulation [53]. 
 
Calorie restriction has been found to increase SIRT1 expression, which in turn modifies the 
cell’s response to stress and aging. SIRT1 exerts a protective effect by preventing DNA 
damage, mutations and genomic instability, as well as reducing oxidative stress and the damage 
it induces [3]. Resveratrol has been hailed as a “Sirtuin Activator” due to results from many 
tests conducted both in vitro and in vivo. Barger et al. (2008) shows that resveratrol can mimic 
the CR phenomenon and thereby induce SIRT1 activation and life extension [3, 70].  
 
1.3 Cytoprotective response 
The cell has many defence mechanisms and regulatory systems in place to defend against 
cellular damage and neutralise any threats that the cell might encounter. These cytoprotective 
responses are swift and function efficiently in a healthy cell.  
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1.3.1 The Nuclear factor-erythroid 2-related factor 2-Antioxidant Response Element 
(Nrf2-ARE) dynamic 
Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a transcription factor which is responsible 
for the activation of the antioxidant response element (ARE). This element regulates the 
transcription of enzymes during periods of cellular stress [71]. The ARE is a DNA element that 
is responsible for the coding of antioxidant enzymes, it is activated when stress signals induce 
the activation of Nrf2. Such signals include oxidative stress, decreased antioxidant capacity of 
the cell (GSH), the presence of chemicals capable of redox cycling and the biotransformation 
of xenobiotics into reactive intermediates.  
 
In a resting cell, Nrf2 is retained in the cytoplasm by its inhibitor, Keap1 [15]. This transcription 
factor is very unstable and is thus degraded by proteases through ubiquitylation by Keap1. 
However, when stress signals are received, Nrf2 breaks its association with Keap1 in the 
cytoplasm and translocates to the nucleus, where it heterodimerizes with a small Maf protein, 
a protein thought to play a role as a transcriptional activator of Nrf2. This complex then binds 
to the ARE, inducing the activation of this element [72]. Activation of the ARE results in the 
transcription of genes associated with the antioxidant defence system (Figure11). These 
enzymes are produced in response to stress signals and attempt to remedy the situation to bring 













Figure 11: Schematic diagram of the Nrf2-ARE pathway and its regulation by ROS. 
 
1.3.2 The antioxidant defence system 
Antioxidant defence is initiated by the ARE upon activation by Nrf2. The interaction of Nrf2 
and the ARE results in the production of a number of enzymes that serve to protect the cell 
from oxidative stress. Increased oxidative stress influences a number of processes and could 
conclude in cell death, mutations or carcinogenesis as a result of ROS interaction with 
biological molecules. The concentration of intracellular ROS depends on the rate of removal 
by the antioxidant system as well as the simultaneous rate of ROS production. Antioxidant 
enzymes, such as SOD, CAT and GPx, are necessary to maintain cellular health, since ROS is 




These enzymes function together for optimum detoxification of cellular stressors with 
emphasis on oxidative stress. Superoxide dismutase is found in intracellular cytoplasmic spaces 
and serves to degrade superoxide anions by catalysing their dismutation, resulting in the 
formation of hydrogen peroxide [73]. Catalase functions to reduce oxidative stress mediated 
cellular damage. This ubiquitous enzyme is a tetrameric protein with a heme group present in 
each subunit; it has earned the reputation of being the most efficient enzyme by binding and 
degrading up to 1 million H2O2 molecules per second. Catalase is a cytosolic selenoprotein, 
which serves to protect red blood cells from the oxidative degradation of haemoglobin by 
catalysing the reduction of H2O2 to water [74].  
 
Overexpression of GPx results in increased protection against ROS-mediated assault. This 
enzyme requires several cofactors in order to function optimally; an especially important 
cofactor is the tripeptide thiol, Glutathione (GSH), which consists of γ-glutamate, cysteine and 
glycine [75]. GSH functions as an intracellular and extracellular antioxidant, it is an important 
ROS scavenger and its ratio with glutathione disulfide (GSSG) is a marker of oxidative stress. 
Synthesis of GSH is regulated by two enzymes, γ-glutamylcysteine synthetase (γ-GCS) and 
GSH synthetase, as well as by the concentration of cysteine, since this is a rate-limiting 
substrate for the de novo synthesis of GSH [76]. In turn, GSH regulates the formation of γ-
GCS by negative feedback. The ratio of GSH:GSSG is influenced by GSH reductase, as well 
as the production of ROS and therefore, the activity of GPx. GSH reductase is a constantly 
active enzyme, which serves to promote the reduction of GSSG to GSH in order to allow 
maximal functioning of GPx [77]. Activity of GSH reductase increases upon increased 
oxidative stress. The GSH:GSSG ratio exists at a ratio of greater than 100:1 in a healthy, resting 
cell; however, during oxidative stress conditions, this ratio can decline to 10:1 and even 1:1 in 
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extreme cases [77].   These enzymes function to prevent ROS-induced damage in the cell, 
nonetheless, in times of excessive stress these measures fail and oxidative damage occurs.  
 
1.3.3 DNA damage and Repair 
It is known that oxidative stress can induce DNA strand breakage and eventually mutations, 
which could drive the cell towards cancer initiation [33]. In the event that antioxidant response 
systems fail and DNA damage occurs, the cell possesses multiple repair mechanisms to attempt 
to salvage the damaged DNA. One such example of this repair crew is 8-oxoguanine-DNA-
glycosylase (OGG1), which functions to bring about DNA repair. This glycosylase enzyme 
belongs to a family of base excision repair (BER) proteins. It functions in the BER pathway by 
removing 8-oxoguanine base lesions, which are produced by ROS, via a glycolytic mechanism 
[33]. These lesions are highly mutagenic; they result from mispairs with adenine residues, 
causing a G:C to T:A transverse mutation [78].  
 
In this manner, OGG1 plays a crucial role in the prevention of ROS-induced tumour formation. 
In the event that OGG1 becomes inactive, base lesions could accumulate, thereby increasing 
the likelihood of mutations and the possibility of carcinogenesis. Diminished DNA repair 
capacity is a marker for cancer susceptibility. Therefore, decreased functioning of fundamental 










2. Materials and Methods 
 
2.1 Materials 
All tissue culture consumables were purchased from Whitehead Scientific (Johannesburg, SA). 
The HEK293 cells were obtained from Highveld Biological (Johannesburg, SA). Ochratoxin 
A and resveratrol were purchased from Sigma Aldrich. Methylthiazoltetrazolium (MTT) salt, 
phosphate buffered saline (PBS) tablets and agarose were purchased from Capital Laboratory 
Supplies (Johannesburg, SA). The bicinchoninic acid (BCA) assay kit and tris-chloride were 
purchased from Sigma Aldrich (Johannesburg, SA). Kits and reagents used for luminometry 
(GSH-Glo™ Glutathione Assay kit) were purchased from Promega (United Sates of America 
(USA)).  
 
Reagents for qPCR were purchased from Bio-Rad and the primer sequences were purchased 
from Inqaba Biotechnologies. Western Blotting reagents (Laemmli sample buffer and 
chemiluminescent reagents) were obtained from Bio-Rad (USA). Primary antibodies (rabbit 
anti-Nrf2 (8882) and rabbit anti-pSIRT1 (2314L)) were purchased from Cell Signalling (USA) 
and horse-radish peroxidase (HRP) – conjugated secondary antibodies (anti-rabbit IgG) were 
purchased from Santa Cruz Biotechnology (USA). Proteins were standardised to anti-β-actin 
(A3854) from Sigma Aldrich (USA). All other solvents and salts were purchased from Merck 
Chemicals (Johannesburg, SA). Protein isolation was conducted using CytobusterTM 






2.2 Cell culture 
HEK293 cells were cultured in monolayer (106 cells per 25cm3 culture flask). The cells were 
maintained in complete culture medium (CCM: Dulbecco’s Minimum Essential Media 
(DMEM), 10% foetal calf serum (FCS), 1% Penstrepfungizone (PSF) and 1% L-glutamine (L-
Glut)) and incubated overnight at 37°C in a humidified incubator supplied with 5% CO2. Cells 
were washed with 1.0M PBS. Once 80 % confluent, cells were removed using trypsin and 
agitating the flasks, cells were then counted using the Trypan Blue exclusion assay.  
 
2.3 OTA treatments 
A stock solution of 200µM OTA was prepared in 60% dimethyl sulphoxide (DMSO). Cells 
were treated with a range (0.25µM–50µM) of concentrations to obtain a half maximal 
inhibitory concentration (IC50). 
 
2.4 Methylthiazoltetrazolium (MTT) assay 
The yellow MTT salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is water 
soluble and thus forms a solution when dissolved in 1.0M PBS, which is converted to a water-
insoluble, purple formazan ((2E,4Z)-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan) by 
viable cells (Figure 12) [79]. The reaction is catalysed by mitochondrial reductase, and involves 
the reduction of MTT by reducing molecules, such as nicotinamide adenine dinucleotide 
(NADH). The MTT assay is a colorimetric assay used to determine cell viability by exploiting 
the conversion of MTT to formazan crystals by living cells, the intensity of the formazan 













Figure 12: MTT is reduced to a formazan product by viable cells, via a reaction catalysed by 
mitochondrial reductase. 
 
To determine cell viability cells were seeded into a 96-well microtitre plate (15,000 cells/well) 
and allowed to attach overnight. Attached cells were treated with a range of OTA 
concentrations (0.25µM–50µM) for 24hrs. Treatment media was removed and replaced with 
CCM (100µl) and 20µl MTT salt solution (5mg/ml in PBS). Cells were incubated with the 
MTT salt solution for 4hrs, then discarded and DMSO (100µl) was added; the cells were 
incubated with DMSO for 1hr. Absorbance was read using a Bio-Tek MQx200 
spectrophotometer (SA) at 595nm (reference wavelength 655nm). An inhibitory concentration 
at which 50% of cell growth was inhibited (IC50) was calculated using GraphPad Prism 
Statistical Software (version 5). 
 
2.5 Resveratrol treatments 
Stock solutions of 10mM resveratrol were prepared in 100% DMSO.  Preliminary assays were 
carried out to determine the optimal resveratrol concentrations for all subsequent treatments. 
Cells were treated with 25µM, 50µM and 100µM resveratrol during pre-, post- and co-OTA 
treatments for 24hrs. The cells were then removed and counted according to the requirements 
Mitochondrial 
reductase 
MTT salt Formazan 
  NADH       NAD+ 
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for each assay. Flow cytometry (106 cells/treatment) was used to observe which resveratrol 
concentration greatly decreased the percentage of intracellular ROS, while luminometry (104 
cells/well) was used to detect the levels of intracellular GSH, thus indicating which 
concentration provided a more robust defence against oxidative damage. Based on these 
results, 25µM resveratrol was used for all subsequent assays.  
 
2.6 Cell preparation for assays 
Cells were treated once flasks reached confluency (106 cells/flask). Treatments included a 
control (CCM containing the solvent vehicle, DMSO), the IC50 value of OTA (1.5µM), a 
resveratrol control (CCM containing 25µM resveratrol) and a co-treatment (1.5µM OTA and 
25µM resveratrol in CCM). Treatments were incubated over 24hrs. Cells were removed by 
trypsinisation and agitation, the Trypan Blue method of cell counting was employed to 
determine cell viability and number as required per assay performed (Figure 13). The control 










Figure 13: Diagram of a haemocytometer chamber used to calculate cell number and viability 
(Sigma Aldrich BioFiles).  
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2.7 Glutathione (GSH) and glutathione disulfide (GSSG) assay 
Glutathione is a low molecular weight thiol consisting of three amino acids – cysteine, glycine 
and glutamine. GSH functions as a free radical scavenger by donating electrons (e-) to free 
radicals, thereby detoxifying reactive species [80]. This free radical scavenger, which exists in 
reduced (GSH) or oxidised (GSSG) forms, is tightly regulated by a number of enzymes 
governing its production and functioning (Figure 14). GPx uses GSH as a cofactor to detoxify 
H2O2 to water, glutathione reductase (GR) manages the form of GSH present in the cell, and 
glucose-6-phosphate dehydrogenase (G6PD) maintains the level of nicotinamide adenine 













Figure 14: The GSH system of detoxification. 
 
The GSH Assay (per GSH-Glo™ Glutathione Assay (Promega) protocol) was used to 









(104cells/well) were seeded in a luminometry plate in 6 replicates. Standards (0-50µM) were 
added in triplicate to generate a standard curve of known GSH concentrations. Tris (2-
carboxyethyl) phosphine (TCEP) was used as a reducing agent to reduce GSSG to GSH and 
thus measure the concentration of total GSH+GSSG in the cells. TCEP was added to cells in 
triplicate and agitated for 10sec, the GSH-Glo™ reagent (50µl) was added to each well; the 
plate was agitated for 30sec, and incubated in the dark (RT, 30min). The luciferin detection 
agent (100µl) was added to each sample and incubated as previously described (RT, 15min). 
The plates were read on a Modulus™ microplate luminometer (Turner Biosystems, Sunnyvale, 




































2.8 Comet assay 
The comet assay is a sensitive method used to measure single and double DNA strand breaks. 
It was first described by Ostling and Johanson [81] and was subsequently modified by Singh 
et al [82]. These modifications involved the lysis of cells embedded in agarose using a lysis 
solution, containing a detergent and a high salt concentration, in an alkaline environment. The 
comet assay exploits the fact that DNA is supercoiled in nature and it is negatively charged. 
The phosphate ions present in the ribose-phosphate backbone of DNA confers a negative 
charge and allows for the migration of DNA towards the anode when subjected to 
electrophoresis in an alkaline solution. When strand breaks occur, DNA loses this supercoiled 
structure and the free ends are able to migrate towards the anode [83]. 
 
Low melting point agarose (LMPA) was used to prepare the gels. The first gel layer (700µl 1% 
LMPA) was formed on a frosted microscope slide, covered with a coverslip and incubated at 
4°C (10min). Thereafter, the coverslip was removed, a second gel layer (1.5µl GR Red dye, 
25µl cell suspension (104 cells) in 175µl 0.5% LMPA) was added, coverslips were placed over 
slides and incubated as above. Coverslips were removed and a third layer was added (0.5% 
LMPA, 200µl) onto the second. Once the third layer solidified, coverslips were removed, slides 
were submerged in an ice-cold cell lysing solution (10mM Tris (pH 10), 1% Triton X-100, 
2.5M NaCl, 100mM EDTA and 10% DMSO) and incubated in the dark (4°C, 1hr).  
 
After incubation, the lysing solution was removed, slides were placed in an electrophoresis 
tank filled with electrophoresis buffer (300mM NaOH and 1mM Na2EDTA) and allowed to 
equilibrate for 20min. The electrophoresis tank was then sealed and a constant voltage was 
applied (25V, 35 minutes). After electrophoresis, slides were washed thrice (5min each) with 
neutralisation buffer (0.4M Tris, pH 7.4). The comet tails were visualised using an intercalating 
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dye, GR Red, an Olympus IX5I inverted fluorescent microscope (510-560nm excitation, 
590nm emission filters) and analySIS Image Processing Software (Novell). Approximately 50 
comets per treatment (3 replicates) were counted and analysed by measuring tail length (µm).  
 
2.9 Quantitative polymerase chain reaction (qPCR) 
PCR is sensitive, specific technique that can be used for the amplification and detection of 
nucleic acid sequences. This technique requires the following components: 
- A DNA target sequence to be amplified 
- Forward and reverse primers that are complementary to the 3’ ends of the forward and 
reverse strands of the target sequence 
- Taq DNA Polymerase, which catalyses the DNA synthesis process 
- Deoxynucleoside triphosphates (dNTPs) that are used to synthesise new strands of 
DNA  
- MgCl2, which acts as a DNA stabiliser and is required for optimal functioning of Taq 
polymerase 
- A specific buffer solution which maintains the required conditions, such as pH, during 
a PCR reaction 
This technique requires the interaction of chemically synthesised primers that are 
complementary to the target DNA flanking sites, dNTPs and Taq DNA polymerase. The 
primers bind to the complementary flanking sites of the DNA template. DNA polymerase then 
incorporates dNTPs to the 3’-OH- ends of the primers, thereby amplifying the target region. 
 
There are three clear steps to a PCR reaction; 1) Denaturation, 2) Annealing and 3) Extension. 
To begin the PCR reaction, the temperature is raised to 95˚C so that denaturation can take 
place. This step ensures that the DNA double strand (dsDNA) is “melted” into DNA single 
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strands (ssDNA). The annealing step involves lowering the temperature to ±55˚C to allow the 
primers to bind to the target gene [84]. Primer binding provides DNA polymerase with a 
foundation to begin copying the DNA strand. The polymerase used is Taq polymerase, from 
the bacteria Thermus aquaticus. Taq polymerase is a thermostable enzyme that catalyses the 
synthesis of new DNA strands [85]. However, the optimum functioning temperature for Taq 
polymerase is 72˚C, thus the temperature is raised to 72˚C in the extension step to facilitate 
DNA synthesis [84]. These three steps conclude one cycle of a PCR reaction (Figure 16). This 
cycle is repeated 30 to 40 times to achieve acceptable amplification of the target sequence.  
 
Conventional PCR successfully amplifies target DNA regions, but it does not quantify the 
sample. On the other hand, qPCR allows for the amplification and simultaneous quantification 
of the target gene in a sample. Firstly, RNA must be isolated and used to synthesise single 
stranded complementary DNA (cDNA) by reverse transcription. This cDNA is then used for 
qPCR. The qPCR cycles are similar to conventional PCR cycles (Figure 16), however, qPCR 
incorporates SYBR Green, a DNA-binding dye, which allows quantification to occur. The dye 
binds to DNA as amplification occurs and emits fluorescence as the cycles progress. A house-
keeping gene is detected with the target gene in qPCR. This provides a control by which to 
measure the quantity of the amplified target gene. Data is analysed by comparing the target 





























Figure 16: Representation of one cycle of the PCR target DNA amplification process.  
 
2.9.1 RNA extraction  
RNA was isolated following an in-house protocol using Trizol. Trizol reagent (500µl) was 















to eppendorfs and stored in Trizol at -80ºC overnight. Chloroform (100µl) was added to thawed 
samples and incubated (RT, 3min). Thereafter, cell suspensions were centrifuged (12,000g, 
4ºC, 15min) and the aqueous phase was removed. Next 250µl isopropanol was added and 
samples were left overnight at -80ºC. Samples were thawed and centrifuged (12,000g, 4ºC, 
20min). The supernatant was discarded, the pellet was retained and washed with 75% cold 
ethanol (500µl) and centrifuged (7,400g, 4ºC, 15min). Ethanol was removed and samples were 
allowed to air dry. The pellet was resuspended in nuclease-free water (15µl) and incubated 
(RT, 3min). The RNA was quantified using the Nanodrop2000 spectrophotometer and the 
A260/A280 ratio was used to assess the RNA integrity. The concentration of RNA was 
standardised to 2500ng/µl and used to prepare cDNA. 
 
2.9.2 cDNA Synthesis  
The standardised RNA was used to synthesise cDNA using the iScript cDNA synthesis Kit 
(Bio-Rad) as per manufacturer’s instructions. Briefly, tubes were prepared for each sample and 
a reaction mix was prepared. The reaction mix contained 4µl 5X iScript reaction mix, 1µl 
iScript reverse transcriptase, 11µl nuclease-free water and 4µl of each RNA sample was added 
to this solution. The tubes were then incubated in a thermocycler (GeneAmp® PCR System 
9700, Applied Biosciences) for 40 minutes (5 minutes at 25˚C, 30 minutes at 42˚C and 5 
minutes at 85˚C).  
 
2.9.3 qPCR 
Gene expression was analysed using the iScript SYBR Green PCR kit (Bio-Rad), according to 
the manufacturer’s instructions. Each reaction volume totalled 25µl (12.5µl SYBR Green, 1µl 
forward primer, 1µl reverse primer, 9µl nuclease-free water and 1.5µl cDNA sample). The 
mRNA expressions of OGG1, CAT, SOD, GPX and Nrf2 was investigated using specific 
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primers (Table 1). This assay was carried out using 6 replicates per treatment and β-Actin as a 
house-keeping gene. The initial denaturation occurred at 95ºC (4min), followed by 37 
denaturation cycles (95ºC, 15sec). An annealing step was then carried out for 40sec dependent 
on specific annealing temperatures of each gene (OGG1 - 60ºC; Nrf2, Cat and GPx - 58ºC; 
SOD - 57ºC). An extension step occurred (72ºC, 30 sec), followed by a plate read of 37 cycles 
(CFX96 Touch™ Real-Time PCR Detection System). The method described by Livak and 
Schmittgen was employed to determine the changes in relative mRNA expression, where 2-∆∆Ct 
represents the fold change observed in mRNA expression [86]. 
 
Table 1: List of primer sequences used for qPCR 
 
Primer                             Primer Sequence 
 
OGG1 sense 5’-GCATCGTACTCTAGCCTCCAC-3’ 
OGG1 antisense 5’-AGGACTTTGCTCCCTCCAC-3’ 
CAT sense 5’-TAAGACTGACCAGGGCATC-3’ 
CAT antisense 5’-CAACCTTGGTGAGATCGAA-3’ 
SOD sense 5’-GAGATGTTACACGCCCAGATAGC-3’ 
SOD antisense 5-AATCCCCAGCAGTGGAATAAGG-3’ 
GPx sense 5’-GACTACACCCAGATGAACGAGC-3’ 
GPx antisense 5’-CCCACCAGGAACTTCTCAAAG-3’ 
Nrf2 sense 5’-AGTGGATCTGCCAACTACTC-3' 
Nrf2 antisense 5'-CATCTACAAACGGGAATGTCTG-3' 
β-actin sense 5’-TGACGGGTCACCCACACTGTGCCCAT-3’ 







2.10 SDS-PAGE and Western Blotting 
2.10.1 Protein isolation and sample preparation 
Crude protein was isolated from cells using CytobusterTM supplemented with phosphatase and 
protease inhibitors. Cytobuster reagent (250µl) was added to flasks following treatments; the 
cells were scraped, transferred to eppendorfs and incubated on ice for 10min. The cell solution 
was then centrifuged (10,000g, 4°C, 5min). The supernatant was used for protein quantification 
using the Bicinchoninic Acid (BCA) Assay. The BCA assay is a colorimetric assay used to 
determine the concentration of protein in each sample tested [87]. This assay functions by 
observing the formation of chromophores formed by a reaction between the BCA solution and 
cuprous ions (Cu1+). Cuprous ions are produced during the interaction of proteins with alkaline 
Cu2+, this is known as the biuret reaction (Figure 14) [87]. This assay can be used to determine 

































Bovine Serum Albumin (BSA) standards (0-1mg/ml) were prepared. Samples and standards 
(25µl) were pipetted into a 96-well microtitre plate in duplicate. The BCA reagent was prepared 
in a ratio of 198µl BCA: 4µl CuSO4 per reaction, and 200µl of this working solution was added 
to each well. The plate was incubated at 37°C for 30min, thereafter, the absorbance was read 
on a Bio-Tek MQx200 spectrophotometer (SA) at 562nm (Figure 15). A standard curve was 











Figure 18: Colour changes seen in the BCA assay. 
 
Laemmli buffer (dH2O, 0.5M Tris-HCl (pH 6.8), glycerol, 10% SDS, β-mercaptoethanol, 1% 
bromophenol blue) was added to each sample (1:1, total volume 200µl), and heated to 100°C 
(5min). This buffer is also known as the tris-glycine buffer system. The components each have 
specific functions; glycerol provides weight to the protein sample and allows the sample to 
settle at the bottom of the wells to prevent dissolution of the protein, β-mercaptoethanol cleaves 
disulfide bonds between molecules to allow for an elongated monomeric molecule and 
bromophenol blue acts as a tracking dye so visualisation of the dye front is possible.  
BCA Assay – Colorimetric reaction 
based on protein concentration 
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2.10.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and Transfer 
The sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) method was 
developed by Laemmli, he showed that proteins can be separated and observed during 
migration through a gel [89]. This method is extremely important and widely used in the 
biochemistry field. Proteins are separated according to their molecular weights by migrating 
through polyacrylamide gels [90]. These proteins are then transferred to nitrocellulose 
membranes and probed using antibodies [91]. The powerful detergent, SDS, serves two 
functions based on two functional areas, namely the hydrophobic (dodecyl) component and the 
highly charged (sulphate) component. The dodecyl section interacts with hydrophobic amino 
acids in proteins. The detergent elongates globular proteins into elongated molecules and 
confers negative charges along the length of the protein, thus facilitating migration towards a 
positive electrode. The percentage of polyacrylamide gel dictates the migration of proteins, 
since larger molecules do not migrate easily through high percentage acrylamide gels. This 
process removes the charge and shape of the protein as a variable, thus the migration depends 
entirely on molecular weight.  
 
Protein samples were separated on SDS polyacrylamide gel (7.5% resolving gel and 4% 
stacking gel) for 1hr at 150V. Thereafter, the proteins were transferred onto nitrocellulose 
membranes using the Transblot® Turbo™ Transfer system (Bio-Rad). Nitrocellulose 
membranes and polyacrylamide gels are sandwiched between fibre pads, a current is passed 


















Figure 19: Components of the transfer system. 
 
2.10.3 Western blotting 
Proteins of interest can be detected by probing the nitrocellulose membranes with specific 
antibodies. Firstly, the membrane must be blocked with a BSA solution to prevent non-specific 
binding of the antibodies. Secondly, the membrane is incubated with a primary antibody against 
the specific protein of interest, this is followed by an incubation with a secondary HRP-
conjugated antibody. The secondary antibody allows for the visualisation of the protein of 















2 buffer soaked fibre pads 



















Figure 20: Chemiluminescent detection of the antibody-antigen reaction. 
 
 Membranes were blocked with 3% BSA in Tris buffered saline (TTBS, 25 mM Tris (pH 7.6) 
150 mM NaCl, 0.05% Tween 20) for 30min, and incubated with a primary antibody (1:1,000, 
3% BSA in TTBS at 4°C overnight). Antibodies used were anti-Nrf2 and anti-phospo SIRT1. 
Protein concentrations were standardised to anti-β-actin. After incubation, the primary 
antibody was removed, membranes were washed thrice with TTBS (10min) and incubated with 
a HRP-conjugated secondary antibody in 3% BSA (1:10,000) for 1hr. Following incubation, 
membranes were washed with TTBS. Clarity Western ECL Substrate (Bio-Rad) (400µl) was 
added to the membranes and images were captured using a gel documentation system (UviTech 
Alliance 2.7). The membranes were then quenched with hydrogen peroxide, incubated in a 
Chemiluminescent detection 







blocking solution (3% BSA, 1hr, RT), rinsed twice in TTBS and probed with HRP-conjugated 
anti-β-actin (house-keeping protein). Densitometry analysis was performed using the UviTech 
Analysis software and protein expression was read as relative band intensity (RBI). Protein 
expression was reported as RBI of the protein of interest divided by the RBI of the loading 
control. The fold change was calculated by normalizing the RBI of the samples against the RBI 
of β-actin, this ratio was used to calculate the fold change.  
 
2.11 Flow cytometry - Intracellular ROS  
Fluorescence activated sell sorting (FACS) is carried out using a flow cytometer. This 
instrument is able to measure characteristics of individual cells flowing in a stream of fluid, 
using fluorescent probes and optical detectors [4]. Flow cytometry is able to detect intracellular 
ROS by measuring the fluorescence emitted per cell analysed. This emitted fluorescence is 
collected by optical detectors and specific wavelengths are isolated. The light is then converted 











Figure 21: Flow cytometer components [4]. 
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Dichlorodihydrofluorescein diacetate (DCFDA) (Santa Cruz Biotechnology) was used to 
detect intracellular ROS, since it is a cell permeant that reacts with superoxide, hydroxyl and 
peroxynitrite radicals. DCFDA passively diffuses into cells and is retained and cleaved by 
intracellular esterases. The DCFDA probe is non-fluorescent, however, upon oxidation by 
ROS, it is converted to a very fluorescent compound, 2’, 7’,-dichlorofluorescein (DCF).  
Intracellular ROS was determined following 24hr incubation with OTA and resveratrol. 
Treated cells were removed and counted as per assay requirement, (500,000 cells were required 
per treatment). Cells were incubated in phenol red free media, supplemented with 10% FCS 
and 10µM DCFDA, in the dark (45min, 37ºC). Thereafter, cells were rinsed thrice with 1.0M 
PBS and centrifuged (400g, RT, 5min). Once the washes were complete, the cells were 
suspended in 150µl 0.1M PBS and analysed using an Accuri™ C6 flow cytometer (Becton 
Dickinson). Live cells were gated and the fluorescence of DCF was measured (emission: 492-
495nm; excitation: 517-527nm). A total of 50,000 events were acquired and analysed using 
CFlow Plus Software.  
 
2.12 Statistical analysis 
Statistical analyses were performed using a one-way analysis of variance (ANOVA) test and 
the Students’ T-test, using GraphPad Prism version 5.0 (GraphPad Software, San Diego, 
California). All data is expressed as mean ± standard error of mean. All assays were run in 











3.1 MTT Assay 
The MTT assay was used to determine an IC50 value of OTA in HEK293 cells after 24hr 
treatment (Figure 22). The resulting dose-response curve was used to calculate the IC50 of OTA 
which was used for all subsequent assays.  Using this curve, the IC50 value was calculated as 










Figure 22: Percentage viability of cells exposed to OTA over 24 hours. An IC50 of 1.5µM was 
calculated from the dose-response curve. 
 
3.2 Analysis of Intracellular ROS 
Flow cytometry was used to measure intracellular ROS production (Figure 2). These results 
showed that resveratrol significantly reduced intracellular ROS in HEK293 cells (p<0.0001). 
Both the OTA and OTA+Resveratrol treatments significantly reduced ROS when compared to 
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control cells ((Figure 2); p=0.0048). This result indicates that resveratrol aids in significantly 










Figure 23: Resveratrol (25µM) significantly decreased the percentage of intracellular ROS 
(***p<0.0001), while OTA and OTA+Resveratrol treatments decreased the values of ROS 
when compared to control cells (*p=0.0048). 
 
3.3 Assessment of DNA damage and repair  
Resveratrol has been shown to significantly reduce the extent of DNA damage resulting from 
exposure to OTA. Comet tails were significantly longer in OTA-treated cells (44.81 ± 1.516; 
p<0.0001), as compared to the controls (Figure 3). In contrast, resveratrol significantly 
decreased comet tail lengths compared to all other treatments ((Figure 3); 11.69 ± 0.695; 
p<0.0001). Interestingly, cells co-treated with OTA+Resveratrol showed significantly 
decreased comet tail lengths as compared to cells only exposed to OTA ((Figure 3); 29.03 ± 
1.110 vs 44.81 ± 1.516; p<0.0001).  OTA significantly increased the mRNA expression of 
OGG1, a DNA glycosylase enzyme, while resveratrol significantly decreased its expression 
((Figure 3); p=0.0294). However, OTA+Resveratrol co-treated cells significantly increased 



































OGG1 expression, strongly suggesting a synergistic effect on the expression of this DNA repair 
enzyme ((Figure 3); p=0.0027) A plausible explanation for this may be that increased comet 


















Figure 24: Assessment of DNA damage showing images of A) comet tails and B) the 
measurement of comet tail lengths. OTA increased comet tail lengths (***p<0.0001), while 
resveratrol significantly decreased lengths (***p<0.0001). C) The fold change analysis of 
OGG1 mRNA expression in cells exposed to OTA and resveratrol indicates that OTA 
significantly increased, while resveratrol significantly decreased expression of OGG1 mRNA 
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(p<0.05). OTA+Resveratrol co-treated cells showed a significant increase in OGG1 mRNA 
expression when compared to OTA-exposed cells, which correlates to the events seen in the 
comet assay.  
 
3.4 Measurement of GSH and GSSG concentrations 
Intracellular concentration of GSH and GSSG was determined using luminometry. Cells co-
treated with OTA+Resveratrol significantly increased concentrations of both GSH and GSSG 
compared to other treatments (p=0.0117). In contrast, resveratrol-treated cells contained low 
concentrations of GSH, and high concentrations of GSSG when compared to control and OTA-












Figure 25: Concentrations of GSH and GSSG in HEK293 cells after exposure to OTA and 
resveratrol. The OTA+Resveratrol co-treatment increased the concentrations of GSH and 






























3.5 qPCR analysis of antioxidant response 
The mRNA expression of genes associated with the antioxidant response was assessed by 
qPCR. The expression of Nrf2, an antioxidant defence regulator, was significantly increased 
by both OTA and resveratrol ((Figure 5A); p=0.0048) and OTA+Resveratrol (p<0.0001). The 
antioxidant enzyme gene expressions of GPx ((Figure 5B); p=0.0048), CAT ((Figure 5C); 
p=0.0048) and SOD ((Figure 5D); p=0.0048) were significantly increased by both OTA and 
resveratrol.  
 
Also, the co-treatment of OTA+Resveratrol induced a greater increase in GPx (p=0.0002), 
CAT (p=0.0003) and SOD (p=0.0003) than observed in other treatments. These results show 
































Figure 26: OTA, resveratrol and OTA+Resveratrol significantly increased the mRNA 
expression of genes associated with the antioxidant response in HEK293 cells – A) Nrf2 
(*p<0.05), B) GPx (*p<0.05), C) CAT (*p<0.05) and D) SOD (*p<0.05).  
 
3.6 Western blotting 
The protein levels of Nrf2 and pSIRT1 was determined using western blotting. Nrf2 protein 
expression was significantly decreased by resveratrol and OTA+Resveratrol ((Figure 6); 
p=0.0048 and p=0.0002 respectively). Phosphorylation of SIRT1 protein in both resveratrol 
and OTA+Resveratrol treatments was significantly increased ((Figure 6); p=0.0048 and 















































































p=0.0002 respectively), indicating that resveratrol had exerted its influence on the activation 










Figure 27: Western blot images and relative fold change in protein levels of Nrf2 and pSIRT1 
in response to OTA and resveratrol exposure. Resveratrol and OTA+Resveratrol significantly 
decreased the expression of Nrf2 (**p<0.05). Resveratrol and OTA+Resveratrol significantly 
increased the levels of pSIRT1 (***p=0.0002 and **p<0.05 respectively), indicating increased 









































OTA is a mycotoxin that frequently contaminates a wide range of foods. Once ingested OTA 
exerts its toxic effects via several pathways; one such pathway in the kidney is the increase in 
oxidative stress, resulting in DNA damage and progressive renal failure in individuals who 
chronically ingest foods contaminated with high concentrations of OTA [1]. OTA poses a 
health risk to populations in developing countries, as they depend largely on agricultural crops 
often heavily contaminated with fungi, such as Aspergillus and Penicillium [27]. OTA has been 
identified as an aetiological agent in BEN [27]. The exact mechanism of OTA toxicity is still 
relatively unknown and in this study we provide insight into the biochemical changes induced 
by OTA in HEK293 kidney cells.   
 
Resveratrol is a phytoalexin commonly produced in grape skins as a result of damage or 
infection with Botrytis cinerea, a fungus known to contaminate grape crops [16]. This 
compound is known to have antioxidant characteristics and chemo-preventive potential, and 
has been proposed as a treatment for illnesses, such as cardiovascular disease, diabetes and 
cancer [92]. We determined whether resveratrol could prevent cytotoxicity induced by OTA in 
kidney cells.  
 
Under normal conditions ROS serves to regulate intracellular signaling, however, under 
conditions of excessive ROS production, intracellular signaling is compromised and 
irreversible cellular damage can occur [29]. Oxidative stress will result in cytotoxicity and 
altered cellular functioning [73]. Lipids, proteins and DNA are susceptible to ROS attack and 
subsequent damage [30].  
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OTA decreased intracellular ROS (as determined by FACS), but induced single strand DNA 
breaks as seen in the comet assay. Acute exposure to OTA (1.5µM) resulted in significant DNA 
strand breaks in HEK293 cells, suggesting that OTA is genotoxic. In comparison to control 
cells, OTA significantly increased the lengths of comet tails, while resveratrol significantly 
decreased comet tail lengths by 63% and also limited damage by OTA, as observed in the 
OTA+Resveratrol effects. The co-treatment resulted in decreased comet tail lengths when 
compared to controls, and significantly decreased comet tail lengths by 35% compared to OTA-
treated cells. Also, the percentage of intracellular ROS was lowest in resveratrol-treated cells. 
When cellular DNA damage occurs, the cell activates DNA repair enzymes, such as OGG1 – 
a DNA glycosylase. The mRNA expression of OGG1 was increased. OGG1 removes 8-
oxoguanine base lesions, which could possibly result in mutations and carcinogenesis if left to 
accumulate [11]. The HEK293 cells increased the expression of OGG1 in response to OTA-
induced DNA damage, as observed by the increased comet tail lengths. However, OGG1 
expression was lowest in resveratrol-treated cells with shortest comet tails, while the 
OTA+Resveratrol co-treatment induced the highest expression of OGG1, coupled with a 
significant decrease in comet tail length. The co-treatment of OTA+Resveratrol seemed to 
synergistically increase the expression of OGG1 that may have afforded a protective function, 
and this is evidenced by shorter comet tails. The protective role of resveratrol over DNA 
(single/double strand breaks) can be attributed to its decrease in both intracellular ROS and 
OGG1 expression, thus providing evidence for its protective role and its possible anti-cancer 
potential.  
 
GSH is an important co-factor required for GPx functionality, as it prevents excessive oxidative 
stress accumulation [76]. The OTA+Resveratrol co-treatment significantly increased 
concentrations of intracellular GSH and GSSG, suggesting that resveratrol is active in the 
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regeneration of GSH. This observation is further substantiated in cells that received resveratrol-
only had higher concentrations of total GSH than the control and OTA-treated cells.   
 
In addition, resveratrol significantly increased Nrf2 mRNA expression in all treatments, 
suggesting that resveratrol upregulates the antioxidant defence. Nrf2 activates the ARE and 
influences the increased transcription of detoxification enzymes, such as CAT, SOD and GPx. 
Resveratrol significantly increased mRNA expression of SOD, CAT and GPx in all treatments. 
GPx upregulation will increase GSH concentrations, whilst superoxide radicals, such as H2O2 
is detoxified by SOD; CAT and GPx together then convert H2O2 into water [73]. This two-part 
reaction allows for the conversion of toxic species into natural by-products that can be used by 
the cell or easily removed [73].  
 
Nrf2 protein expression however, did not correspond to Nrf2 mRNA expressions. This 
disparity may be attributed to the known protein synthesis inhibitory properties of OTA [93]. 
Although resveratrol attempts to repair the oxidative damage by increasing production of Nrf2 
protein, OTA suppresses this attempt. The decreased Nrf2 expression strongly suggests that 
resveratrol itself mediates the antioxidant defence response, in keeping with its antioxidant 
properties [64]. Resveratrol is known to activate SIRT1, an NAD+-dependent deacetylase. 
SIRT1 has been identified as a positive contributor in many regulatory pathways, such as 
cellular stress response and apoptosis [53]. Protein expression of pSIRT1 was significantly 
increased in both resveratrol treatments. Phosphorylation of SIRT1 results in increased nuclear 
localization of the protein, as well as increased enzymatic activity [94]. The stress protection 
pathway is mediated by SIRT1, increased phosphorylation would influence this function and 
induce deacetylation of stress proteins, such as p53 and PGC-1alpha, causing cellular 






This data provides insight into the workings of the toxin; we are proposing that short term 
effects of OTA contribute to its toxicity. The cells experience a significant increase in the 
antioxidant response due to the recognition of a cytotoxic environment, however, it is not 
possible to sustain an increased protective response while DNA damage occurs. Our data 
suggests that OTA exhausts the cell’s antioxidant reservoir during acute exposure and thus the 
cell is left vulnerable as the exposure period continues.  
 
Taken together, this data suggests resveratrol could be used as a potential treatment for OTA 
toxicity, as well as a possible therapy for other oxidative stress inducing toxins. Regarding the 
information on DNA damage prevention, this research also attests to the potential chemo-
preventive attributes of resveratrol. Based on these findings, it would be worthwhile to further 
investigate the effects of OTA and explore the DNA repair properties of resveratrol in an in 
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Figure 1: Standard curve using known concentrations of BSA to determine the unknown 
concentrations of protein samples in the BCA assay. 
 
2.  
Table 1: Calculation of protein concentrations using equation generated from standard curve 














C 2,852 1,96 2,406 12,542 23,91963004 176,08037 
V 2,472 2,403 2,4375 12,6995 23,62297728 176,3770227 
O 2,71 2,055 2,3825 12,4245 24,14584088 175,8541591 
CR 2,082 2,382 2,232 11,672 25,70253598 174,297464 
OR 3,31 2,515 2,9125 15,0745 19,90115758 180,0988424 













1. Table 1: Raw data of comet tail length measurements (µm)  
C C O O R R OR OR 
39,99 12,9 29,67 36,12 7,74 9,03 42,57 32,25 
42,57 19,35 32,25 45,15 11,61 6,45 37,41 33,54 
41,28 12,9 29,67 42,57 11,61 10,32 21,93 36,12 
43,86 24,51 34,83 39,99 12,9 11,61 24,51 32,25 
43,86 27,09 39,99 38,7 7,74 7,74 21,93 33,54 
28,38 24,51 33,54 36,12 6,45 15,48 24,51 30,96 
43,86 23,22 45,15 34,83 6,45 7,74 19,35 28,38 
38,7 34,83 47,73 38,7 10,32 18,06 15,48 30,96 
43,86 38,7 47,73 43,86 7,74 15,48 25,8 28,38 
39,99 10,32 45,15 39,99 6,45 12,9 21,93 38,7 
41,28 36,12 39,99 42,57 6,45 15,48 29,67 34,83 
49,02 34,83 46,44 46,44 6,45 12,9 29,67 38,7 
32,25 38,7 38,7 50,31 6,45 15,48 34,83 39,99 
24,51 32,25 41,28 47,73 9,03 11,61 32,25 33,54 
29,67 41,28 37,41 46,44 6,45 15,48 32,25 38,7 
28,38 30,96 38,7 52,89 7,74 19,35 41,28 19,35 
32,25 30,96 64,5 56,76 7,74 19,35 16,77 25,8 
37,41 36,12 63,21 59,34 14,19 20,64 19,35 19,35 
32,25 36,12 56,76 52,89 7,74 20,64 27,09 10,32 
16,77 39,99 61,92 67,08 7,74 20,64 29,67 16,77 
27,09 38,7 61,92 51,6 6,45 14,19 28,38 24,51 
18,06 36,12 29,67 64,5 6,45 18,06 39,99 33,54 
32,25 36,12 33,54 56,76 10,32 21,93 37,41 36,12 
19,35 28,38 30,96 58,05 10,32 21,93 29,67 18,06 











1. Table 1: Raw data used to calculate IC50 of OTA. 
Concentration 
Log 
Concentration OD 1 OD 2 OD 3 Mean OD 
Percent 
Viability 
Control 0 0,484 0,463 0,585 0,51066667 100,000 
Vehicle 0 0,556 0,416 0,412 0,46133333 90,339 
0.25µM 2,398 0,352 0,251 0,353 0,31866667 62,402 
0.5µM 2,699 0,527 0,175 0,255 0,319 62,467 
1µM 3 0,312 0,301 0,278 0,297 58,159 
2µM 3,301 0,197 0,258 0,187 0,214 41,906 
5µM 3,699 0,233 0,154 0,105 0,164 32,115 
10µM 4 0,147 0,111 0,16 0,13933333 27,285 
20µm 4,301 0,052 0,065 0,111 0,076 14,883 
















1.  Table 1: Raw flow cytometry data for the measurement of intracellular ROS.   
Sample 1 2 3 4 5 6 7  
Avg % of IC 
ROS 
measurement  
C1 53,79% 50,32% 53,79% 50,32% 53,79% 50,32% 53,79% 0,523029 52,30285714 
C1 50,87% 47,92% 50,87% 47,92% 50,87% 47,92% 50,87% 0,496057 49,60571429 
C1 42,49% 39,67% 42,49% 39,67% 42,49% 39,67% 42,49% 0,412814 41,28142857 
O1 23,90% 22,35% 23,90% 22,35% 23,90% 22,35% 23,90% 0,232357 23,23571429 
O2 27,88% 25,59% 27,88% 25,59% 27,88% 25,59% 27,88% 0,268986 26,89857143 
O2 27,00% 24,62% 27,00% 24,62% 27,00% 24,62% 27,00% 0,2598 25,98 
R 1 21,07% 19,49% 21,07% 19,49% 21,07% 19,49% 21,07% 0,203929 20,39285714 
R 1 20,89% 19,25% 20,89% 19,25% 20,89% 19,25% 20,89% 0,201871 20,18714286 
R 1 20,84% 19,25% 20,84% 19,25% 20,84% 19,25% 20,84% 0,201586 20,15857143 
OR2 29,81% 28,00% 29,81% 28,00% 29,81% 28,00% 29,81% 0,290343 29,03428571 
OR2 30,15% 28,28% 30,15% 28,28% 30,15% 28,28% 30,15% 0,293486 29,34857143 







Figure 1: Scatter plots of flow cytometry data used to calculate the percentage of ROS in 
each sample set.  
